Colon cancer: AI-based marker can improve quality of treatment

A Norwegian-led research group has developed a clinically useful prognostic marker using deep learning and digital scanning of conventional hematoxylin and eosin-stained tumor tissue sections. The assay has been extensively evaluated in large, independent patient populations, correlates with and outperforms established molecular and morphological prognostic markers, and gives consistent results across tumor and nodal stage.

Photo
Usind deep learning and digital scanning of conventional hematoxylin and eosin-stained tumor tissue sections, researchers have developed a clinically useful prognostic marker .
Source: Institute for Cancer Genetics and Informatics, Oslo University Hospital

The biomarker stratified stage II and III patients into sufficiently distinct prognostic groups. The tool has the potential to guide the selection of adjuvant treatment by avoiding therapy in very low-risk groups, and at the same time, identifying patients who would benefit from more intensive treatment regimes. The new method, which detects the DoMore-v1-CRC marker, is called histotyping.

More than 12,000,000 image tiles from patients with a distinctly good or poor disease outcome from four cohorts were used to train a total of 10 convolutional neural networks purpose-built for classifying super-sized heterogeneous images. A prognostic biomarker integrating the 10 networks was determined using patients with a non-distinct outcome.

The researchers tested 920 patients with slides prepared in the UK, which were independently validated according to a predefined protocol in 1122 patients treated with single-agent capecitabine using slides prepared in Norway. All cohorts included only patients with resectable tumors, and a formalin-fixed, paraffin-embedded tumor tissue block available for analysis. The primary outcome was cancer-specific survival. Eight-hundred twenty-eight patients from four cohorts had a distinct outcome and were used as a training cohort to obtain clear ground truth. 1645 patients had a non-distinct outcome and were used for tuning.

The biomarker provided a hazard ratio for poor versus good prognosis of 3·84 (95% CI 2·72–5·43; p<0·0001) in the primary analysis of the validation cohort. After adjusting for established prognostic markers significant in univariable analyses of the same cohort, (pN stage, pT stage, lymphatic invasion, venous vascular invasion) was the hazard ratio 3·04 (2·07–4·47; p<0·0001).

The method can differentiate between different stages of cancer and between patients in equal stages, but with different prognoses, using deep learning and neural networks. With today's pathological methods, as many as 80% of patients end up with an unclear prognosis. With the new AI-based method, is this figure has reduced to 12%. The researchers behind the marker expect it to be a useful tool for the choice of treatment. "The prognostic tools we have today, especially in the most common cancers, are far too coarse. We can with more precise prognostication, avoid both over- and undertreatment. Both will be important for the patient and the clinical services," says Sigbjørn Smeland, director of the Cancer Clinic, Oslo University Hospital.

Subscribe to our newsletter

Related articles

AI identifies features associated with cancer recurrence

AI identifies features associated with cancer recurrence

An AI has successfully found features in pathology images from human cancer patients, without annotation, that could be understood by human doctors.

AI detects even the smallest metastases

AI detects even the smallest metastases

Researchers have developed a new algorithm that enables automated detection of metastases at the level of single disseminated cancer cells in whole mice.

Deep learning identifies molecular patterns of cancer

Deep learning identifies molecular patterns of cancer

An AI platform can analyze genomic data extremely quickly, picking out key patterns to classify different types of colorectal tumors and improve the drug discovery process.

Deep learning assists in detecting malignant lung cancers

Deep learning assists in detecting malignant lung cancers

Radiologists assisted by deep learning based software were better able to detect malignant lung cancers on chest X-rays.

Microscopy: AI converts 2D images into 3D

Microscopy: AI converts 2D images into 3D

Researchers have devised a technique that extends the capabilities of fluorescence microscopy, which allows scientists to precisely label parts of living cells and tissue with dyes that glow under special lighting.

Cancer: AI identifyies patients for immunotherapy

Cancer: AI identifyies patients for immunotherapy

Stomach and colorectal cancer: Identifying patients at an early stage who are suitable for artificial intelligence immunotherapy.

A step towards mending a broken heart

A step towards mending a broken heart

Bioengineers have developed a prototype patch that does the same job as crucial aspects of heart tissue.

Superior bio-ink for 3D printing pioneered

Superior bio-ink for 3D printing pioneered

Engineers have developed a “bio-ink” for 3D printed materials that could serve as scaffolds for growing human tissues to repair or replace damaged ones in the body.

A 'multitasking' AI tool quickly extracts cancer data

A 'multitasking' AI tool quickly extracts cancer data

To better leverage cancer data for research, scientists are developing an artificial intelligence-based natural language processing tool to improve information extraction from textual pathology reports.

Popular articles